Disclosure. Objectives. New Anticoagulants 6/5/2014 GHASSAN HADDAD M.D FHM. South Miami hospital Director of the Anticoagulation clinic.
|
|
- Amanda Manning
- 5 years ago
- Views:
Transcription
1 /5/1 New Anticoagulants: Opportunities, Challenges and Practical Considerations GHASSAN HADDAD M.D FHM. Chief of Hospital Medicine i South Miami hospital Director of the Anticoagulation clinic. Financial Interest/ Affiliation Grant/Research Support Consultant Disclosure Commercial Organization(s) Portela None Objectives New Anticoagulants 1. Outline approved indications and opportunities for the new anticoagulants using the evidence from clinical trials. Highlight common clinical scenarios surrounding the use of these new drugs 3. Describe limitations and practical considerations when using these anticoagulants Indications Opportunities Evidence-base Challenges Practical Considerations 1
2 /5/1 New Anticoagulants Current Anticoagulants XIIa Vitamin K Antagonist XIa IXa VIIa Unfractionated Thrombin Inhibitors heparins Low molecular Bivalirudin weight heparins Lepirudin Enoxaparin Argatroban Tinzaparin Dalteparin Xa VIIIa IIa (thrombin) Factor Xa Inhibitors Fondaparinux Va FIBRIN VTE=venous thromboembolism. Walenga JM, et al. Thromb Res ;:1-3. New and Emerging Anticoagulants XIIa Factor Xa Inhibitors Idraparinux Apixaban Edoxaban Otamixaban Betrixaban YM15 LY AVE5 Thrombin Inhibitors Dabigatran Etexilate XIa IXa Walenga JM, et al. Thromb Res ;:1-3. Xa IIa (thrombin) FIBRIN VIIa VIIIa Va Pharmacodynamics & Pharmacokinetics of Old and New Anticoagulants Parameter Apixaban Dabigatran Enoxaparin Fondaparinux Route Oral Oral Subcutaneous Subcutaneous Oral Oral Bioavailability (%) Time to peak concentration (h) Clotting factors inhibited Xa IIa IIa, Xa Xa Xa II, VII, IX, X Route of Primarily Renal Primarily Primarily Primarily Primarily elimination (%) fecal (5), () renal renal renal () bile renal (5) bile () Half life (h) Routine None None None None None INR/PT, coagulation (plasma (Ecarin clotting (plasma (plasma (plasma frequently monitoring antifactor Time optional) antifactor antifactor antifactor Xa optional) Xa optional) Xa optional) Xa optional) Farley et al. Orthopedics 9;3(1):35.
3 /5/1 CHADS -> CHA DS VASc HAS-BLED CHADS Risk Score CHADS- Score VASc Risk CHF 1 CHF or LVEF < 1 % Hypertension 1 Hypertension 1 Age > 75 1 Age > 75 Diabetes 1 Diabetes 1 Stroke/TIA/ Thromboembolism Stroke or TIA Vascular Disease 1 From ESC AF Guidelines Age guidelines/guidelines Documents/guidelines-afib-FT.pdf Female 1 Clinical Points Risk Factors / Bleeds/ Letter Characteristic Awarded Score 1 Pt years 1.13 H Hypertension A Abnormal renal & 1 or 1. liver function (1 point each) S Stroke 1.7 B Bleeding L Labile INRs 1 E Elderly 1 7 D Drugs or alcohol 1 or (1 point each) 9 Pisters et al. Chest 1; 13: Epidemiology of Atrial Fibrillation Estimated to affect >. million Americans Prevalence increasing as population ages Presence of AF confers a 5-fold higher risk for ischemic stroke Most common arrhythmia requiring hospitalization 1, hospital discharges/year Associated with >9, deaths/year Risk for recurrent severe stroke is increased.-fold in patients not treated with anticoagulants Lloyd-Jones D, et al. Circulation. 1;11:e-e15. AF=atrial fibrillation. Millions) Adults With AF ( Future of Atrial Fibrillation: ATRIA Study Projected Number of Adults With AF in the US From 1995 to Year Go AS, et al. JAMA. 1;5; AF=atrial fibrillation. 3
4 /5/1 Unmet Needs in Clinical Practice Surrounding Atrial Fibrillation Numerous food and drug interactions, narrow therapeutic index, requires monitoring, has a slow onset of action and has an unpredictable dose response Guidelines is recommended for stroke prevention in most patients with AF but it is underused Many physicians do not adhere to the guidelines Stroke risk stratification has had little effect on warfarin use Patient Management Elderly patients benefit most from an anticoagulant, but are less likely to receive it, largely because of their perceived risk of falling or bleeding Only ~5% of patients treated with warfarin are in the therapeutic range Ansell et al. Chest. 1;119:S-3S. Waldo et al. J Am Coll Cardiol. 5;:1793. RCTs of the New Anticoagulants RE-LY ROCKET-AF ARISTOTLE ENGAGE AF Drug Dabigatran Apixaban Endoxaban Dose 15, 11 (15) 5 (.5), 3 Investigated (mg) Dose Frequency Twice daily Once daily Twice daily Once daily Drug Target Factor Iia Factor Xa Factor Xa Factor Xa Subjects (n) 1,113 1, ~15, ~1, Trial Design Open label Double blind Double blind Double blind Blind dose Double dummy Double dummy Double dummy Primary Efficacy Endpoint Stroke/SEE Stroke/SEE Stroke/SEE Stroke/SEE Dose Adjustment for No Yes Yes Yes Drug Clearance (mg) Non-inferiority Hazard Ratio Margin RE-LY: A Non-inferiority Trial 1 efficacy outcome=stroke or systemic embolism 1 safety outcome=major bleeding Non-inferiority margin=1. Open (INR.-3.) N= Atrial fibrillation 1 Risk Factor Absence of contra-indications 951 centers in countries R Dabigatran Etexilate 11mg BID N= Blinded Dabigatran Etexilate 15mg BID N= RE-LY: 1 Outcome Superiority Analysis D 11mg vs D 15mg vs D 11mg D 15mg Annual Annual Annual RR P- RR P- Rate Rate Rate 95% CI value 95% CI value Stroke or 1.5% 1.1% 1.7% <.1 Systemic Embolism Stroke 1.% 1.% 1.%.9.1. < PROBE=Prospective Randomized Open Trial With Blinded Adjudication of Events. INR=international normalized ratio. Connolly SJ, et al. N Engl J Med. 9;31: RE-LY=Randomized Evaluation of Long-Term Anticoagulation Therapy. BID=two times per day.
5 t /5/1 Dabigatran 11 mg (D11) vs in Atrial Fibrillation Dabigatran vs 15 mg (D15) vs in Atrial Fibrillation Percent 1 D Percent 1 t D Stroke or SE RRR 9% (-11 to ) Major hemorrhage Stroke RRR % (7 to 31) RRR % (-13 to ) NNT 7 (9 to 17) Outcomes (At median y) Death RRR 9% (-3 to ) Stroke or SE RRR 3% (1 to 7) NNT 9 (5 to 19) Major hemorrhage Stroke RRR 7% (-7 to 19) RRR 3% (19 to 9) NNT 9 ( to 17) Outcomes (At median y) Death RRR 1% ( to 3) Connolly et al. N Engl J Med 9;31: Connolly et al. N Engl J Med 9;31: Dabigatran 15 mg (D15) vs 11 mg (D11) in Atrial Fibrillation Higher-dose Dabigatran Reduced Stroke but not Major Hemorrhage Compared to Percent 1 t D15 D Stroke or SE RRR 7% (9 to ) NNT 1 ( to 371) Stroke Death RRR 3% (11 to ) RRR 3% (-11 to 15) NNT 1 ( to 35) Outcomes (At median y). 5. Major hemorrhage RRR 1% ( to 3) Conclusion In patients with Afib, D15 twice daily reduced risk for stroke and systemic embolism more than warfarin and had similar rates of major hemorrhage Impact on Practice First oral anticoagulant in > 5 years. Dabigatran has no food or drug interactions. Now endorsed by the AHA/ACCF/HRS Guidelines Connolly et al. N Engl J Med 9;31:
6 /5/1 Nonvalvular AF, history of stroke, TIA, or embolism, or of the following: HF, HTN, age 75 years, or diabetes mellitus ROCKET-AF Trial: Treatment period 1-3 months mg once daily 15 mg once daily (creatinine clearance 3-9 ml/min at entry) R N=1, target INR,.5 (INR range:.-3.) Day 1 Day 3 after last dose In AF patients with a moderate to high risk of stroke, does rivaroxaban reduce the risk of major vascular events compared with warfarin? 1 study endpoint: composite of all-cause stroke and non-cns systemic embolism endpoints: composite of TIA, all-cause death, vascular death, and MI 1 safety endpoint: composite of major and clinically relevant non-major bleeding events Randomization completed in June 9; follow-up completed 1 Follow-up: up to years (until 5 primary outcome events have been observed) TIA=transient ischemic attack. HF=heart failure. HTN=hypertension INR=international normalized ratio. Patel et al. N Engl J Med 11; 35:3-91. End of treatment Follow-up Rocket-AF: Baseline Demographics CHADS Score (mean) (%) 3 (%) (%) 5 (%) (%) (N=71) (N=79) Prior VKA Use (%) 3 Congestive Heart Failure (%) 3 Hypertension (%) 9 91 Diabetes Mellitus (%) 39 Prior Stroke/TIA/Embolism (%) Prior Myocardial Infarction (%) 17 1 CHADS =a score that estimates the risk of stroke in patients with AF and AF=atrial fibrillation. includes Congestive heart failure, Hypertension, Age 75, Diabetes VKA=vitamin K antagonists. mellitus, and prior incidence of Stroke or Transient Ischemic Attack. TIA=transient ischemic attack. Patel et al. N Engl J Med 11; 35:3-91. Event Rates Are per 1 Patient-Years Based on Protocol Compliant on Treatment Population Primary Efficacy Outcome Stroke and Non-CNS Embolism Event Rate (%) Cumulative E Event Rate HR (95% CI):.79 (.,.9) P-value Non-inferiority: < Days From Randomization No. at risk: Patel et al. N Engl J Med 11; 35:3-91. ROCKET-AF: Primary Efficacy Outcome Stroke and Non-CNS Embolism Better Event Rate Event Rate HR (95% CI) On.79 Treatment (.5,.95) N=1,13 ITT N=1,171 Better.1. Event rates are per 1 patient-years. Based on safety on treatment or ITT through site notification populations. Patel et al. N Engl J Med 11; 35:3-91. TTR 57.%. (.7,1.3) ITT=intention to treat. P-value
7 /5/1 ROCKET-AF: Major and Non-Major Bleeding Hazard Ratio Outcome (n=71) (n=79) (95% CI) P-value Major and Non-major Bleeding ( ) Major Bleeding (.9-1.) > g/dl hemoglobin drop (1.3-1.) Transfusion ( ) Critical organ bleeding ( ) Bleeding causing death ( ) Intracranial hemorrhage (.7-.9) Patel et al. N Engl J Med 11; 35:3-91. Rocket-AF: Summary Efficacy: was noninferior to warfarin for prevention of stroke and non-cns embolism was superior to warfarin while patients were taking study drug By intention-to-treat, rivaroxaban was non-inferior to warfarin but did not achieve superiority Safety: Similar rates of bleeding and adverse events Less ICH and fatal bleeding with rivaroxaban Conclusion: is a proven alternative to warfarin for moderate- or high-risk patients with AF Patel et al. N Engl J Med 11; 35:3-91. CNS=central nervous system. ICH=intracranial hemorrhage. CHADS Scores: RE-LY and ROCKET-AF RE-LY 1 ROCKET-AF CHADS Dabigatran Dabigatran Score 11mg 15mg Mean % 3.% 1.% 3.7% 35.% 37.% 13% 13% 3-3.7% 3.% 3.1% 7% 7% 1. Connolly SJ, et al. N Engl J Med. 9;31: Patel et al. N Engl J Med 11; 35:3-91. Atrial Fibrillation with at Least One Additional Risk Factor for Stroke Inclusion risk factors Randomize Age 75 years double blind, Prior stroke, TIA, or SE double dummy HF or LVEF % Diabetes mellitus (n = 1,1) Hypertension Apixaban 5 mg oral twice daily (.5 mg BID in selected patients) Major exclusion criteria Mechanical prosthetic valve Severe renal insufficiency Need for aspirin plus thienopyridine (target INR -3) /warfarin placebo adjusted by INR/sham INR based on encrypted point-of-care testing device Primary outcome: stroke or systemic embolism Hierarchical testing: non-inferiority for primary outcome, superiority for primary outcome, major bleeding, death 7
8 /5/1 Primary Outcome Stroke (ischemic or hemorrhagic) or systemic embolism P (non-inferiority)<.1 1% RRR Apixaban 1 patients, 1.7% per year 5 patients, 1.% per year HR.79 (95% CI,..95); P (superiority)=.11 No. at Risk Apixaban Efficacy Outcomes Apixaban Outcome (N=91) (N=91) P HR (95% CI) Event Rate Event Rate Value (%/yr) (%/yr) Stroke or systemic embolism* (.,.95).11 Stroke (.5,.95).1 Ischemic or uncertain (.7, 1.13). Hemorrhagic (.35,.75) <.1 Systemic embolism (SE) (., 1.75).7 All-cause death* (.,.99).7 Stroke, SE, or all-cause death (.1,.9).19 Myocardial infarction (., 1.17).37 * Part of sequential testing sequence preserving the overall type I error Major Bleeding ISTH definition 31% RRR Bleeding Outcomes Outcome Apixaban (N=9) Event Rate (%/yr) (N=95) Event Rate (%/yr) HR (95% CI) P Value Primary safety outcome: ISTH major bleeding* (.,.) <.1 Intracranial.33.. (.3,.5) <.1 Apixaban 37 patients,.13% per year patients, 3.9% per year HR.9 (95% CI,..); P<.1 No. at Risk Apixaban Gastrointestinal (.9 (.7, 1.15) 15) Major or clinically relevant non-major bleeding.7.1. (.1,.75) <.1 GUSTO severe bleeding (.35,.) <.1 TIMI major bleeding (.,.7) <.1 Any bleeding (.,.75) <.1 * Part of sequential testing sequence preserving the overall type I error
9 /5/1 Summary Treatment with apixaban as compared to warfarin in patients with AF and at least one additional risk factor for stroke: Reduces stroke and systemic embolism by 1% (p=.1) Reduces major bleeding by 31% (p<.1) Reduces mortality by 11% (p=.7) 7) with consistent effects across all major subgroups and with fewer study drug discontinuations on apixaban than on warfarin, consistent with good tolerability. Einstein DVT: Study Design Randomized, open-label, event-driven, non-inferiority study Up to hours heparins / fondaparinux treatment permitted before study entry 99 primary efficacy outcomes needed Confirmed symptomatic DVT without symptomatic PE N=3,9 R Treatment period: 3, or 1 months 15 mg bid x 3 wks followed by mg po qd Enoxaparin 1. mg/kg bid 5 days, followed by VKA INR range -3 Day 1 Day 1 3-day observation period EINSTEIN Investigators. N Engl J Med. 1 Dec 3;33(): Primary Efficacy Outcome Analysis Enoxaparin / VKA (n=1,731) (n=1,71) n (%) n (%) First symptomatic recurrent VTE 3 (.1) 51 (3.) Recurrent DVT 1 (.) (1.) Recurrent DVT + PE 1 (<.1) () Non-fatal PE (1.) 1 (1.) Fatal PE / unexplained death where (.) (.3) PE cannot be ruled out Hazard ratio superior non-inferior inferior p=.7 for superiority (two-sided) p=.1 for non-superiority (one-sided) ITT population EINSTEIN Investigators. N Engl J Med. 1 Dec 3;33(): Principal Safety Outcome Analysis Enox / VKA HR (n=1,71) (n=1,711) (95% CI) n (%) n (%) p value First major or clinically relevant 139 (.1) 13 (.1).97 (.7-1.) Non-major bleeding p=.77 Major bleeding 1 (.) (1.) Contributing to death 1 (<.1) 5 (.3) In a critical site 3 (.) 3 (.) Associated with fall in Hb g/dl 1 (.) 1 (.7) and/or transfusion of units Clinically relevant non-major 19 (7.5) 1 (7.1) bleeding Safety population EINSTEIN Investigators. N Engl J Med. 1 Dec 3;33():
10 /5/1 Eighth ACCP Recommendations: Total Knee or Hip Replacement LMWH (grade 1A) Adjusted-dose warfarin (grade 1A) Fondaparinux (grade 1A) IPC (grade 1B-Only for TKA) LDUH, ASA, dextran, GCS, VFP not recommended (1A) Optimal duration of prophylaxis after THR and TKR: at least 7-1 days of LMWH (grade 1A) Extended out-of-hospital prophylaxis for THR or HFS for upto -35 days (grade 1A) Geerts et al. CHEST ; 31S-53S ents % of patie : Prophylaxis in Major Orthopedic Surgery VTE/Death * P <.1 ** P =.1 * * Record 1 Record Record 3 Record Eriksson B, et al. N Engl J Med. ;35: Kakkar AK, et al. Lancet. ;37: Lassen MR, et al. N Engl J Med. ;35:77-7. Turpie AG, et al. Lancet. 9;373(97): * ** tients % of pa Major Bleeding Record 1 Enoxaparin Record Record 3 Record 1, = total hip replacement Record 3, = total knee replacement Record Pharmacokinetic Properties of New Anticoagulants Preoperative Interruption of New Oral Anticoagulants: An Empiric Formulation New Anticoagulants Dabigatran Apixaban Direct factor Mode of IIa (thrombin) Direct factor Direct factor action inhibitor Xa inhibitor Xa inhibitor Bioavailability (F wt ).5% % % Peak action (t max ) 1-3 hrs 1-3 hrs 1-3 hrs Elimination half-life (t 1/ ) 1-17 hrs 9-15 hrs 9-1 hrs Route of clearance 1% renal 5% renal 5% renal Involvement of CYP minor minor minor Douketis. Current Pharmaceutical Design, 1, Vol 1, No 31 Aim for No or Minimal Aim for Mild-moderate Residual Anticoagulant Residual Anticoagulant Effect at Surgery (-5 Drug Effect at Surgery (-3 Drug Half-Lives Separate Half Lives Separate Drug (Half-Life) Renal Function Last Dose & Surgery) Last dose & Surgery) Dabigatran Normal or Mild Last dose: Day -3 Last dose: Day - t 1/ = 1 hrs Impairment before surgery before surgery (CrCl >5 ml/min) (skip doses) (skip doses) t 1/ = 15-1 hrs Moderate Impairment Last dose: Day - to Last dose: Day -3 (CrCl 3-5 ml/min) Day -5 before surgery before surgery (skip - doses) (skip doses) Normal or Mild Last dose: Day -3 Last dose: Day -3 t 1/ = 9 hrs Impairment before surgery before surgery (CrCl >5 ml/min) (skip doses) (skip doses) Apixaban as with rivaroxaban as with rivaroxaban as with rivaroxaban t 1/ = 9 hrs Douketis. Current Pharmaceutical Design, 1, Vol 1, No 31 1
11 /5/1 Postoperative Resumption of New Oral Anticoagulants: An Empiric Formulation Minor surgery or Procedure (low bleeding risk) Major surgery (high bleeding risk) Dabigatran resume on day after surgery resume days after surgery ( hrs postoperatively), ( hrs postoperatively), 15 mg twice-daily 15 mg twice-daily* resume on day after surgery resume days after surgery ( hrs postoperatively), ( hrs postoperatively), 1 mg daily 1 mg daily Apixaban as with rivaroxaban as with rivaroxaban *for patients at high risk for thromboembolism, consider administering a reduced dose of dabigatran eg., mg once-daily) on evening after surgery and on the first postoperative day. Douketis. Current Pharmaceutical Design, 1, Vol 1, No 31 11
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole
More informationStepheny Sumrall, FNP, AGACNP Cardiovascular Clinic of Hattiesburg
Novel Oral Anticoagulants Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for the Treatment of Atrial Fibrillation and Prevention of Stroke Stepheny Sumrall,
More informationNUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More informationNOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationNew Oral Anticoagulant Drugs in the Prevention of DVT
New Oral Anticoagulant Drugs in the Prevention of DVT Targets for Anticoagulants ORAL DIRECT VKAs inhibit the hepatic synthesis of several coagulation factors Rivaroxaban Apixaban Edoxaban Betrixaban X
More informationPros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES
Pros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES Ralph L. Sacco, MS MD FAAN FAHA Olemberg Family Chair in Neurological Disorders Miller Professor of Neurology,
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationThrombosis and Thromboembolsim October Stroke Prevention in Atrial Fibrillation Risk Stratification and Choice of Antithrombotic Therapy
Thrombosis and Thromboembolsim October 2012 Stroke Prevention in Atrial Fibrillation Risk Stratification and Choice of Antithrombotic Therapy Christian T. Ruff, MD, MPH TIMI Study Group Brigham and Women
More informationLessons from recent antithrombotic studies and trials in atrial fibrillation
Lessons from recent antithrombotic studies and trials in atrial fibrillation Thromboembolism cause of stroke in AF Lars Wallentin Uppsala Clinical Research Centre (UCR) Uppsala Disclosures for Lars Wallentin
More informationAnti-thromboticthrombotic drugs
Atrial Fibrillation 2011: Anticoagulation strategies and clinical outcomes Panos E. Vardas President Elect of the ESC, Prof. of Cardiology, University Hospital of Crete Clinical outcomes affected by AF
More informationThe Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for
The Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for Anticoagulation Services Sanford USD Medical Center Sioux Falls,
More informationAnticoagulation: Novel Agents
Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical
More informationDebate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF
Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF Bradley P. Knight, MD Director of Cardiac Electrophysiology Bluhm Cardiovascular Institute Northwestern
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationDavid Stewart, PharmD, BCPS Assistant Professor of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy
David Stewart, PharmD, BCPS Assistant Professor of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy stewardw@etsu.edu At the conclusion of this program, the audience should
More informationOld and New Anticoagulants For Stroke Prevention Benefits and Risks
Old and New Anticoagulants For Stroke Prevention Benefits and Risks September 15, 2014 Jonathan L. Halperin, M.D. The Cardiovascular Institute Mount Sinai Medical Center Disclosure Relationships with Industry
More informationAntithrombotics in Stroke management
Antithrombotics in Stroke management Faculty: Robert Beveridge Relationships with commercial interests: Grants/Research Support: N/A Speakers Bureau/Honoraria: Astra Zeneca, Bayer, Boerhinger Ingelheim,
More informationAnticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationScoring Systems in AF 8/10/2016. Strategies in the Prevention of Atrial Fibrillation-Related Strokes. Overview
Strategies in the Prevention of Atrial Fibrillation-Related Strokes Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania September
More informationTherapeutic Advances for the Management of Thrombosis: Navigating the New Paradigm. Formulary and Contract Manager SelectHealth
Therapeutic Advances for the Management of Thrombosis: Navigating the New Paradigm Jeffrey D Dunn PharmD MBA Jeffrey D. Dunn, PharmD, MBA Formulary and Contract Manager SelectHealth Faculty Disclosure
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationAnticoagulation Therapy in LTC
Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation
More informationADVANCES IN ANTICOAGULATION
ADVANCES IN ANTICOAGULATION The Clinicians Perspective Claudine M. Lewis Cardiologist OUTLINE Indications for anticoagulants Review - Physiology of Hemostasis Types of anticoagulants New anticoagulants
More informationAtrial Fibrillation. 2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018
2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018, MSc, FACP, SFHM Division of Hospital Medicine Henry Ford Hospital Detroit, USA Clinical Associate Professor of Medicine Wayne
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationUtilizing Anticoagulants for Atrial Fibrillation Related Stroke Prevention
Utilizing Anticoagulants for Atrial Fibrillation Related Stroke Prevention Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania
More informationAnticoagulation Beyond Coumadin
Anticoagulation Beyond Coumadin Saturday, September 21, 2013 Crystal Mountain Resort and Spa Pratik Bhattacharya MD, MPH Stroke Neurologist, Michigan Stroke Network; Assistant Professor of Neurology; Wayne
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationEvents after discontinuation of randomized treatment at the end of the ARISTOTLE trial
Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial Christopher Granger, John Alexander, Michael Hanna, Jerry Wang, Puneet Mohan, Jack Lawrence, Elaine Hylek, Jack Ansell,
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationAnticoagulant therapy, coumadines or direct antithrombins
ATRIAL FIBRILLATION (AF) Anticoagulant therapy, coumadines or direct antithrombins Felicita Andreotti, MD PhD Aggregated Professor Dept of Cardiovascular Sciences, Catholic University, Rome, IT Consultant
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationNovel Anticoagulants PHYSICIANS UPDATE 2014
Novel Anticoagulants PHYSICIANS UPDATE 2014 Farouk Mookadam MD FRCPC FACC MSc Professor College of Medicine Mayo Consultant Cardiovascular Diseases Medical Director Anticoagulation Clinic Assoc Programme
More informationNew Antithrombotic Agents DISCLOSURE
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Research Alexion (PNH) delought@ohsu.edu Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What
More informationXarelto (rivaroxaban)
Xarelto (rivaroxaban) Policy Number: 5.01.575 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Xarelto
More informationNew oral factor Xa inhibitors. Lessons from AVERROES and ARISTOTLE trials
New oral factor Xa inhibitors. Lessons from AVERROES and ARISTOTLE trials Dimitri Richter, MD, FESC, FAHA Head of Cardiac Dept., Athens Euroclinic General Secretary of Hellenic Lipidology Society Member
More informationNew Anticoagulants Therapies
New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations
More informationNew Antithrombotic Agents
New Antithrombotic Agents Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None What I am Talking About 1. New Antithrombotic
More informationUpdate on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell
Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from
More informationAbbreviated Class Update: Anticoagulants, oral and parenteral
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationAn Overview of Non Vitamin-K Antagonist Oral Anticoagulants. Helen Williams Consultant Pharmacist for CV Disease South London
An Overview of Non Vitamin-K Antagonist Oral Anticoagulants Helen Williams Consultant Pharmacist for CV Disease South London Contents Drugs and drug classes Licensed indications and NICE recommendations
More informationKenneth W. Mahaffey, MD and Keith AA Fox, MB ChB
Once-daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation Kenneth W. Mahaffey, MD and Keith AA Fox, MB ChB on behalf
More informationNew options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital
New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,
More informationShow Me the Outcomes!
Show Me the Outcomes! Real-World Safety Data on Oral Anticoagulants in Nonvalvular Atrial Fibrillation Gabby Anderson, PharmD PGY1 Pharmacy Resident anderson.gabrielle@mayo.edu Pharmacy Grand Rounds October
More informationDirect Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT
Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN
More informationAntithrombotic Efficacy and Safety of Dabigatran Etexilate
130419 Luncheon Symposium_2013 춘계심장학회 Antithrombotic Efficacy and Safety of Dabigatran Etexilate Hui-Nam Pak, MD, PhD. Division of Cardiology Yonsei University Health System Atrial Fibrillation Risk of
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationEdoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
More informationOriginal Policy Date
MP 5.01.15 Newer Oral Anticoagulants Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Created with literature search/12:2013 Return to Medical
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationNew Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy
New Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy Hans-Christoph Diener Department of Neurology and Stroke Center University Hospital Essen Germany Conflict of Interest
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationObesity, renal failure, HIT: which anticoagulant to use?
Obesity, renal failure, HIT: which anticoagulant to use? Mark Crowther with thanks to Dr David Garcia and others. This Photo by Unknown Author is licensed under CC BY-SA 1 2 Drug choices The DOACs have
More informationDirect Oral Anticoagulants An Update
Oct. 26, 2017 Direct Oral Anticoagulants An Update Kathleen Heintz, DO, FACC Assistant Professor of Medicine Cooper Heart Institute Direct Oral Anticoagulants: DISCLAIMERS No Conflicts of Interest So what
More informationDrug Class Monograph
Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More informationEdoxaban in Atrial Fibrillation
Edoxaban in Atrial Fibrillation Glenn Gormley, MD, PhD Senior Executive Officer and Global Head of R&D, Daiichi Sankyo Co., Ltd Nov. 4, 2014 Tuesday Background Based on the results of ENGAGE AF-TIMI 48,
More informationA Patient Unsuitable for VKA Treatment
Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following
More informationPractical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease
Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy
More informationNew Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY
New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or
More informationIs Apixaban Effective for the Prevention of Stroke in Patients With Non-Valvular Atrial Fibrillation?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2014 Is Apixaban Effective for the Prevention
More informationPrepared by Pfizer-BMS alliance in response to an unsolicited request Not for further distribution
Prepared by Pfizer-BMS alliance in response to an unsolicited request Not for further distribution AF review Petr Polasek Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document
More informationAF review. Petr Polasek
AF review Petr Polasek Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,
More informationModern management of atrial fibrillation, from blood pressure control to anticoagulation
Modern management of atrial fibrillation, from blood pressure control to anticoagulation Adel Khalifa S. Hamad, BMS, MD, FRCP(Canada) Consultant Cardiologist & Interventional Cardiac Electrophysiologist
More informationNewer Anti-Anginal Agents and Anticoagulants
Newer Anti-Anginal Agents and Anticoagulants Satish Gadi, MD FACC FSCAI Interventional Cardiologist, Cardiovascular Institute of the South (CIS) Baton Rouge Clinical Assistant Professor, Tulane University
More informationNew Age Anticoagulants: Bleeding Considerations
Ontario Regional Blood Coordinating Network March 23, 2012 New Age Anticoagulants: Bleeding Considerations Bill Geerts, MD, FRCPC Thromboembolism Specialist, Sunnybrook HSC Professor of Medicine, University
More informationAnticoagulation: A Changing Landscape. Kelly Matsuda Pharm.D. July 16, Kelly Matsuda Pharm.D. July 16, 2011
Anticoagulation: A Changing Landscape Kelly Matsuda Pharm.D. July 16, 2011 Kelly Matsuda Pharm.D. July 16, 2011 Objectives Review epidemiology of stroke/tia and atrial fibrillation. Review of warfarin
More informationPrimary Prevention of Stroke
Primary Prevention of Stroke Dr Chris Ellis Cardiologist Green Lane CVS Service, Auckland City Hospital & Auckland Heart Group, Mercy Hospital, Auckland 67 Pages Long, 735 References 29 Sub-Headings for
More informationFatal P.E. Historic 1-2% Current %
Dr. (Prof.) Anil Arora MS (Ortho) DNB (Ortho) Dip SIROT (USA) FAPOA (Korea), FIGOF (Germany), FJOA (Japan) Commonwealth Fellow Joint Replacement (Royal National Orthopaedic Hospital, London, UK) Senior
More informationWarfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin
1 2:15 pm The Era of : Selecting the Best Approach to Treatment SPEAKER Gregory Piazza, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Gregory Piazza,
More informationDo s and Don t of DOACs DISCLOSURE
Do s and Don t of DOACs Tom DeLoughery, MD MACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant/Research none Content Expert: Elsevier
More informationReversal of Novel Oral Anticoagulants. Angelina The, MD March 22, 2016
Reversal of Novel Oral Anticoagulants Angelina The, MD March 22, 2016 Argatroban Bivalirudin Enoxaparin Lepirudin Heparin Dabigatran Apixaban 1939 1954 1998 2000 1999 2001 10/2010 7/2011 12/2012 1/2015
More informationIS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS?
IS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS? J.Y. LE HEUZEY Georges Pompidou Hospital, René Descartes University, Paris H E G P Munich, August 27, 2012 Disclosure Consultant / Conferences / Advisory
More informationKCS Congress: Impact through collaboration
Stroke Prevention in Atrial Fibrillation (SPAF) in Kenya Elijah N. Ogola FACC University of Nairobi Kenya Cardiac Society Annual Scientific Congress Mombasa 28 th June 1 st July 2017 KCS Congress: Impact
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationAtrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases?
Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases? Nicolas Lellouche Fédération de Cardiologie Hôpital Henri Mondor Créteil Disclosure Statement of Financial Interest I currently
More informationDrug Class Review Newer Oral Anticoagulant Drugs
Drug Class Review Newer Oral Anticoagulant Drugs Final Original Report May 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationThrombosis. Tom DeLoughery, MD FACP. Oregon Health and Sciences University
Thrombosis Tom DeLoughery, MD FACP Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen, Alexion What I am Talking About New Anticoagulants
More informationAtrial Fibrillation Topics for Today. Clinical Controversies Management of Atrial Fibrillation. Atrial Fibrillation in the ER Topics for Today
Clinical Controversies Management of Atrial Fibrillation Yerem Yeghiazarians, M.D. Associate Professor of Medicine Leone-Perkins Family Endowed Chair in Cardiology Atrial Fibrillation Topics for Today
More informationNew Strategies in the World of Anticoagulant Therapy. October 13, 2012 Elaine M. Hylek, MD, MPH Boston University Medical Center
New Strategies in the World of Anticoagulant Therapy October 13, 2012 Elaine M. Hylek, MD, MPH Boston University Medical Center Presenter Disclosure Information Elaine M. Hylek, MD, MPH Research: NIH/NINDS,
More informationEngage AF-TIMI 48. Edoxaban in AF: What can we expect? Cardiology Update John Camm. St. George s University of London United Kingdom
Cardiology Update 2013 N S N O N H O H N S1 pocket Aryl binding N site O O N H N Cl Engage AF-TIMI 48 Edoxaban in AF: What can we expect? John Camm St. George s University of London United Kingdom Advisor
More informationUpdates in Management of Venous Thromboembolic Disease
Updates in Management of Venous Thromboembolic Disease November 7 th 2018 UHN Emergency Conference Susan Jenkins RN(EC) NP-Adult Thrombosis and Hemostasis Program University Health Network Disclosures
More informationSecondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,
More informationAtrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016
1 Atrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016 Disclosures 2 No conflicts of interest Some questions 3 Should my patient with
More informationA Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations
A Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations Allison Bernard, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics October 25 th,
More informationPerioperative management of antithrombotic drugs: New anticoagulants
Perioperative management of antithrombotic drugs: New anticoagulants Steen Husted Medical-Cardiological Department Aarhus University Hospital Denmark ESC 2010 Perioperative anticoagulation: Risk of bleeding
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More informationEvidences for real-life use in fragile patients: Renal failure and cancer
Evidences for real-life use in fragile patients: Renal failure and cancer Cecilia Becattini Medicina Interna e Cardiovascolare Stroke Unit Università di Perugia Approval number: L.IT.MA.11.2016.1839 Evidences
More informationOral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. The EINSTEIN DVT study.
Oral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. The EINSTEIN DVT study Comments Harald Darius, Berlin Disclosures for Harald Darius Research
More informationNew drugs for anticoagulation so much choice, how do they compare? Dr Patrick Kesteven Newcastle
New drugs for anticoagulation so much choice, how do they compare? Dr Patrick Kesteven Newcastle CONCLUSIONS 1. Arrival of new anticoagulants is a Good Thing. CONCLUSIONS 1. Arrival of new anticoagulants
More informationOral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation
Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe
More informationDisclosures for Albert L. Waldo, M.D.
Alternative Anticoagulation Stgies in Atrial Fibrillation: Issues and Answers? Albert L. Waldo, MD The Walter H. Pritchard Professor of Cardiology, Professor of Medicine, and Professor of Biomedical Engineering
More informationΑντιπηκτική αγωγή 2017 Νέες μελέτες, πραγματικά δεδομένα και κλινική πράξη
Αντιπηκτική αγωγή 2017 Νέες μελέτες, πραγματικά δεδομένα και κλινική πράξη Σταύρος Β. Κωνσταντινίδης, MD, PhD, FESC Καθηγητής Καρδιολογίας Δημοκρίτειο Πανεπιστήμιο Θράκης skonst@med.duth.gr Medical Director
More informationEvaluate Risk of Stroke & Bleeding in AF Patients
XV World Congress of Arrhythmias, Beijing, China - 17-20 September, 2015 Evaluate Risk of Stroke & Bleeding in AF Patients Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation
More informationApixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis
Apixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis Caitlin Reedholm, PharmD PGY1 Pharmacy Resident St. David s South Austin Medical Center November 2, 2018 Abbreviations
More information